Anhui-based pharmaceutical technology company; specific product line not established from available knowledge.
Anhui-based pharmaceutical technology company; specific product line not established from available knowledge.
Moat: none
Headquarters: Anhui, China · Employees: 376
Size Anhui Wanbang Pharmaceutical Technology (301520.SZ) is a China Health Care company (Biotechnology) with a market value of $684M, the 2939th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥51.09 on 18 Nov 2026.
Performance Over six months the shares gained 73.6%, against -23.5% for the median peer and -20.0% for the China market (cap-weighted) — 3rd highest of 19 in its peer set.
Growth Revenue fell 15.3% over the last twelve months (peer median +18.4%); the operating margin is -8.2% (peer median -99.9%).
Valuation It trades at 14.7× enterprise value to sales against a peer median of 6.9× (6th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 45% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is +30 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 7.6 points below its cost of capital (6.8% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥249M | CN¥274M | CN¥378M | CN¥341M | CN¥260M |
| Revenue growth | — | -27% | +11% | +31% | — |
| Gross profit | CN¥62.1M | CN¥61.3M | CN¥139M | CN¥160M | CN¥128M |
| EBITDA | n/a | CN¥20.3M | CN¥68.8M | CN¥115M | CN¥104M |
| Net income | CN¥3.90M | CN¥36.4M | CN¥85.5M | CN¥108M | CN¥98.7M |
| Free cash flow | CN¥21.2M | -CN¥9.63M | CN¥26.2M | -CN¥11.7M | CN¥24.8M |
| Capital expenditure | CN¥3.79M | CN¥19.2M | CN¥41.8M | CN¥86.0M | CN¥50.7M |
| Total debt | CN¥1.96M | CN¥4.29M | CN¥1.60M | CN¥1.00M | CN¥29,884 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301520.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.5% | -7.0% | 8th lowest of 21 |
| 6-month return | +73.6% | -23.5% | 3rd highest of 19 |
| Distance from 52-week high | -42.5% | -47.7% | 6th highest of 21 |
| Revenue growth (TTM) | -15.3% | +18.4% | 4th lowest of 15 |
| Operating margin | -8.2% | -99.9% | 4th highest of 17 |
| EV / Sales | 14.7× | 6.9× | 6th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 44.8% | 4.2% | most demanding of 5 |
| Growth delivered (Del g) | +14.7% | +5.3% | 2nd highest of 5 |
| Hurdle (Req g minus delivered) | +30.1 pp | +1.4 pp | most demanding of 5 |
| ROIC minus cost of capital | -7.6 pp | -15.9 pp | 4th highest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $684M | +74% | -15% | -8% | 14.7× | 44.8% | +14.7% |
| Kura Oncology KURA | United States | $674M | -29% | -24% | -394% | 2.6× | n/a | n/a |
| Prime Medicine PRME | United States | $695M | +35% | +18% | -2,584% | 105.4× | n/a | n/a |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $668M | +292% | n/a | n/a | n/a | n/a | n/a |
| Alphamab Oncology 9966.HK | Hong Kong | $666M | -38% | -32% | -38% | 6.7× | n/a | n/a |
| Solid Biosciences SLDB | United States | $709M | -2% | n/a | n/a | n/a | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $658M | -48% | +153% | -20% | 11.4× | 40.3% | +21.5% |
| Attovia Therapeutics ATTO | United States | $710M | +1,325% | n/a | -5,945% | 220.7× | n/a | n/a |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $715M | n/a | n/a | n/a | n/a | n/a | n/a |
| Shouyao Holdings Beijing 688197.SS | China | $653M | -26% | +4,564% | -92% | 38.1× | n/a | n/a |
| R&G PharmaStudies 301333.SZ | China | $722M | -11% | +21% | 11% | 3.4× | 17.3% | +11.8% |
| Apnimed APMD | United States | $726M | n/a | +380% | -140% | 10.8× | n/a | n/a |
| Geron GERN | United States | $638M | -21% | +19% | -8% | 2.8× | n/a | n/a |
| Beijing SL Pharmaceutical 002038.SZ | China | $736M | -20% | -4% | -119% | 6.9× | -13.5% | -10.9% |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $633M | -27% | 0% | 18% | 4.4× | n/a | n/a |
| Janux Therapeutics JANX | United States | $631M | -28% | +133% | -599% | n/a | n/a | n/a |
| Aura Biosciences AURA | United States | $743M | -4% | n/a | n/a | n/a | n/a | n/a |
| Getein Biotech 603387.SS | China | $625M | -13% | +8% | 21% | 2.6× | -8.9% | -1.3% |
| Inventiva IVA.PA | France | $763M | -36% | -100% | -307,063% | 12,169.8× | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $764M | -50% | n/a | -108% | 21.1× | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $771M | -57% | +160% | -62% | 3.2× | n/a | n/a |